...
exel-img

Exelixis Inc, Common Stock

EXEL

NSQ

$33.29

-$0.39

(-1.16%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$9.62B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
21.729
Volume info-icon
This is the total number of shares traded during the most recent trading day.
6.43M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.51
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$19.2 L
$36.97 H
$33.29

About Exelixis Inc, Common Stock

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameEXELSectorS&P500
1-Week Return-4.97%-2.12%-3%
1-Month Return-3.92%-3.42%-0.73%
3-Month Return26%-11.13%2.87%
6-Month Return53.2%-5.74%7.17%
1-Year Return43.37%3.97%25.31%
3-Year Return78.21%1.05%28.38%
5-Year Return79.85%34.37%81.89%
10-Year Return2460.77%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue967.77M987.54M1.43B1.61B1.83B[{"date":"2019-12-31","value":52.88,"profit":true},{"date":"2020-12-31","value":53.96,"profit":true},{"date":"2021-12-31","value":78.4,"profit":true},{"date":"2022-12-31","value":88.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue33.10M36.27M52.87M57.91M72.55M[{"date":"2019-12-31","value":45.62,"profit":true},{"date":"2020-12-31","value":50,"profit":true},{"date":"2021-12-31","value":72.88,"profit":true},{"date":"2022-12-31","value":79.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit934.68M951.27M1.38B1.55B1.76B[{"date":"2019-12-31","value":53.18,"profit":true},{"date":"2020-12-31","value":54.12,"profit":true},{"date":"2021-12-31","value":78.63,"profit":true},{"date":"2022-12-31","value":88.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin96.58%96.33%96.32%96.41%96.04%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.74,"profit":true},{"date":"2021-12-31","value":99.73,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":99.44,"profit":true}]
Operating Expenses565.21M841.21M1.10B1.35B1.59B[{"date":"2019-12-31","value":35.62,"profit":true},{"date":"2020-12-31","value":53.01,"profit":true},{"date":"2021-12-31","value":69.04,"profit":true},{"date":"2022-12-31","value":85.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income369.47M110.06M286.67M201.48M170.88M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":29.79,"profit":true},{"date":"2021-12-31","value":77.59,"profit":true},{"date":"2022-12-31","value":54.53,"profit":true},{"date":"2023-12-31","value":46.25,"profit":true}]
Total Non-Operating Income/Expense56.60M40.64M15.16M65.93M168.78M[{"date":"2019-12-31","value":33.53,"profit":true},{"date":"2020-12-31","value":24.08,"profit":true},{"date":"2021-12-31","value":8.98,"profit":true},{"date":"2022-12-31","value":39.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income398.11M130.84M294.15M234.35M257.52M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":32.86,"profit":true},{"date":"2021-12-31","value":73.89,"profit":true},{"date":"2022-12-31","value":58.87,"profit":true},{"date":"2023-12-31","value":64.69,"profit":true}]
Income Taxes77.10M19.06M63.09M52.07M49.76M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.72,"profit":true},{"date":"2021-12-31","value":81.83,"profit":true},{"date":"2022-12-31","value":67.54,"profit":true},{"date":"2023-12-31","value":64.54,"profit":true}]
Income After Taxes321.01M111.78M231.06M182.28M207.76M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.82,"profit":true},{"date":"2021-12-31","value":71.98,"profit":true},{"date":"2022-12-31","value":56.78,"profit":true},{"date":"2023-12-31","value":64.72,"profit":true}]
Income From Continuous Operations321.01M111.78M231.06M182.28M92.07M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.82,"profit":true},{"date":"2021-12-31","value":71.98,"profit":true},{"date":"2022-12-31","value":56.78,"profit":true},{"date":"2023-12-31","value":28.68,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income321.01M111.78M231.06M182.28M207.76M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.82,"profit":true},{"date":"2021-12-31","value":71.98,"profit":true},{"date":"2022-12-31","value":56.78,"profit":true},{"date":"2023-12-31","value":64.72,"profit":true}]
EPS (Diluted)1.020.350.710.570.74[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.31,"profit":true},{"date":"2021-12-31","value":70.1,"profit":true},{"date":"2022-12-31","value":55.88,"profit":true},{"date":"2023-12-31","value":72.55,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

EXEL
Cash Ratio 3.02
Current Ratio 3.93
Quick Ratio 3.88

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

EXEL
ROA (LTM) 12.81%
ROE (LTM) 20.20%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

EXEL
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

EXEL
Trailing PE 21.76
Forward PE 21.79
P/S (TTM) 4.62
P/B 4.23
Price/FCF 37
EV/R 4.14
EV/Ebitda 13.56
PEG 2.27

FAQs

What is Exelixis Inc share price today?

Exelixis Inc (EXEL) share price today is $33.29

Can Indians buy Exelixis Inc shares?

Yes, Indians can buy shares of Exelixis Inc (EXEL) on Vested. To buy Exelixis Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EXEL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Exelixis Inc be purchased?

Yes, you can purchase fractional shares of Exelixis Inc (EXEL) via the Vested app. You can start investing in Exelixis Inc (EXEL) with a minimum investment of $1.

How to invest in Exelixis Inc shares from India?

You can invest in shares of Exelixis Inc (EXEL) via Vested in three simple steps:

  • Click on Sign Up or Invest in EXEL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Exelixis Inc shares
What is Exelixis Inc 52-week high and low stock price?

The 52-week high price of Exelixis Inc (EXEL) is $36.97. The 52-week low price of Exelixis Inc (EXEL) is $19.2.

What is Exelixis Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Exelixis Inc (EXEL) is 21.729

What is Exelixis Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Exelixis Inc (EXEL) is 4.23

What is Exelixis Inc dividend yield?

The dividend yield of Exelixis Inc (EXEL) is 0.00%

What is the Market Cap of Exelixis Inc?

The market capitalization of Exelixis Inc (EXEL) is $9.62B

What is Exelixis Inc’s stock symbol?

The stock symbol (or ticker) of Exelixis Inc is EXEL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top